Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Medicine and Dentistry

• Patient 68%
• Cardiovascular Disease 18%
• Cardiovascular System 18%
• Therapeutic Procedure 18%
• Patient with Type 2 Diabetes 13%
• Inpatient 13%
• Incidence 13%
• Myocardial Infarction 9%
• Maturity Onset Diabetes of the Young 9%
• Apoplexy 9%
• Hazard Ratio 9%
• Intention-to-Treat Analysis 9%
• Glucagon-Like Peptide-1 Agonist 9%
• Amaurosis 9%
• Person 9%
• Cardiovascular Effect 4%
• Adverse Event 4%
• Follow up 4%
• Pancreas Cancer 4%
• Chemotherapeutic Agent 4%
• Glycemic 4%
• Subcutaneous Injection 4%
• Drug 4%
• Thyroid Medullary Carcinoma 4%
• Voice 4%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Death 18%
• Incidence 13%
• Non Insulin Dependent Diabetes Mellitus 9%
• Glucagon Like Peptide 1 Receptor Agonist 9%
• Heart Infarction 9%
• Blindness 9%
• Adverse Event 4%
• Subcutaneous Injection 4%
• Drug 4%
• Pancreas Cancer 4%
• Tolerability 4%
• Acute Pancreatitis 4%
• Thyroid Medullary Carcinoma 4%